Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929559 | 0.97 | F2 (0.46) | F2F10PLGPLAUST14 | |
| SCHEMBL13222794 | 0.92 | F2 (0.48) | F2F10PLGPLAUST14 | |
| SCHEMBL12929570 | 0.84 | NPSR1 (0.43) | F2F10PLGPLAUST14 | |
| SCHEMBL19308219 | 0.83 | F2 (0.46) | F2F10PLGPLAUST14 | |
| SCHEMBL12929561 | 0.82 | LMNA (0.46) | F2F10PLGPLAUST14 | |
| SCHEMBL12929565 | 0.82 | CHRNB2 (0.43) | F2F10PLGPLAUST14 | |
| SCHEMBL12929572 | 0.82 | F2 (0.43) | F2F10PLGPLAUST14 | |
| SCHEMBL19308210 | 0.81 | F2 (0.48) | F2F10PLGPLAUST14 | |
| SCHEMBL12929501 | 0.78 | F2 (0.43) | F2F10PLGPLAUST14 | |
| SCHEMBL12929500 | 0.78 | SMN1; SMN2 (0.43) | F2F10PLGPLAUST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | UNIVERSITE DE SHERBROOKE (CA) | 2017-11-02 | — | — | US | disclosed |
| US-9365853-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | SOCPRA Sciences Sante et Humaines S.E.C. | 2016-06-14 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | F2 954/4885F10 1803/4885PLG 160/4885 |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | DNPEP, ANPEP, PEPD | F2 954/4885F10 1803/4885PLG 160/4885 |
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | MMP7, MATR3, ADAMTS1 | F2 995/4885F10 321/4885PLG 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.